JP2015509707A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509707A5 JP2015509707A5 JP2014553750A JP2014553750A JP2015509707A5 JP 2015509707 A5 JP2015509707 A5 JP 2015509707A5 JP 2014553750 A JP2014553750 A JP 2014553750A JP 2014553750 A JP2014553750 A JP 2014553750A JP 2015509707 A5 JP2015509707 A5 JP 2015509707A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variant
- polypeptide
- length
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 85
- 150000001413 amino acids Chemical class 0.000 claims description 72
- 230000002163 immunogen Effects 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 71
- 229920001184 polypeptide Polymers 0.000 claims 70
- 108091033319 polynucleotide Proteins 0.000 claims 32
- 102000040430 polynucleotide Human genes 0.000 claims 32
- 239000002157 polynucleotide Substances 0.000 claims 32
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 241000700605 Viruses Species 0.000 claims 16
- 239000013604 expression vector Substances 0.000 claims 15
- 229960005486 vaccine Drugs 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 206010059866 Drug resistance Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 230000000798 anti-retroviral effect Effects 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 description 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382031.8A EP2620446A1 (en) | 2012-01-27 | 2012-01-27 | Immunogens for HIV vaccination |
| EP12382031.8 | 2012-01-27 | ||
| PCT/EP2013/051596 WO2013110818A2 (en) | 2012-01-27 | 2013-01-28 | Immunogens for hiv vaccination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018041572A Division JP6749357B2 (ja) | 2012-01-27 | 2018-03-08 | Ｈｉｖワクチン接種のための免疫原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509707A JP2015509707A (ja) | 2015-04-02 |
| JP2015509707A5 true JP2015509707A5 (OSRAM) | 2016-03-17 |
| JP6306514B2 JP6306514B2 (ja) | 2018-04-04 |
Family
ID=47603800
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553750A Active JP6306514B2 (ja) | 2012-01-27 | 2013-01-28 | Ｈｉｖワクチン接種のための免疫原 |
| JP2018041572A Active JP6749357B2 (ja) | 2012-01-27 | 2018-03-08 | Ｈｉｖワクチン接種のための免疫原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018041572A Active JP6749357B2 (ja) | 2012-01-27 | 2018-03-08 | Ｈｉｖワクチン接種のための免疫原 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9988425B2 (OSRAM) |
| EP (3) | EP2620446A1 (OSRAM) |
| JP (2) | JP6306514B2 (OSRAM) |
| KR (2) | KR102108149B1 (OSRAM) |
| CN (2) | CN110372798A (OSRAM) |
| AU (2) | AU2013213564B2 (OSRAM) |
| BR (1) | BR112014018396B1 (OSRAM) |
| CA (1) | CA2862172C (OSRAM) |
| ES (1) | ES2932407T3 (OSRAM) |
| IL (2) | IL233771B (OSRAM) |
| IN (1) | IN2014DN06164A (OSRAM) |
| MX (2) | MX358711B (OSRAM) |
| NZ (3) | NZ734689A (OSRAM) |
| RU (2) | RU2648791C2 (OSRAM) |
| WO (1) | WO2013110818A2 (OSRAM) |
| ZA (1) | ZA201405204B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| TW201639852A (zh) | 2008-12-09 | 2016-11-16 | 吉李德科學股份有限公司 | 用於製備可用作類鐸受體調節劑之化合物的中間體化合物 |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| US10072046B2 (en) * | 2014-03-21 | 2018-09-11 | Nutech Ventures | Non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) and methods of using |
| EP4140485A1 (en) | 2014-07-11 | 2023-03-01 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
| UY36298A (es) | 2014-09-16 | 2016-04-29 | Gilead Science Inc | Formas sólidas de un modulador del receptor tipo toll |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| CN114828884A (zh) * | 2019-05-22 | 2022-07-29 | 埃利克斯疗法公司 | 用于疫苗的剂量方案 |
| WO2020237027A1 (en) * | 2019-05-22 | 2020-11-26 | Gilead Sciences, Inc. | Combination of a tlr7 modulating compound and an hiv vaccine |
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| AU2021270777A1 (en) | 2020-05-12 | 2022-11-10 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| CR20230312A (es) | 2021-01-14 | 2023-08-31 | Gilead Sciences Inc | Vacunas contra el vih y métodos de uso |
| WO2024084441A1 (en) | 2022-10-19 | 2024-04-25 | Aelix Therapeutics, S.L. | Combination hiv vaccine |
| EP4417974A1 (en) | 2023-02-17 | 2024-08-21 | Fundació Privada Institut de Recerca de la SIDA-Caixa | Cd33 as a biomarker of hiv control |
| WO2025017540A1 (en) | 2023-07-20 | 2025-01-23 | Aelix Therapeutics, S.L. | Method of treatment of hiv infection with vaccine |
| CN118389553A (zh) * | 2024-03-01 | 2024-07-26 | 中国科学技术大学 | 免疫增效rna分子及其组合物、疫苗与试剂盒 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787901A (fr) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | Vaccin antivariolique |
| US6858712B1 (en) | 1984-08-22 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Cloning and expression of HTLV-III DNA |
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US6294322B1 (en) | 1988-01-26 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
| US5081226A (en) | 1986-12-30 | 1992-01-14 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic peptides sharing sequence homology with the HIV envelope protein |
| US5976541A (en) | 1988-01-26 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope |
| US6210873B1 (en) | 1987-08-28 | 2001-04-03 | Board Of Regents, The University Of Texas System | Methods and compositions for the priming of specific cytotoxic T-lymphocyte response |
| US5128319A (en) | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
| GB8918200D0 (en) | 1989-08-09 | 1989-09-20 | Medical Res Council | The peptide fragments of hiv |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US7319000B1 (en) | 1992-09-16 | 2008-01-15 | Board Of Regents, The University Of Texas System | Compositions and methods for eliciting immune or anti-infective responses |
| JPH08511007A (ja) | 1993-06-09 | 1996-11-19 | コノート ラボラトリーズ リミテッド | タンデム合成ｈｉｖ−１ペプチド |
| PL192784B1 (pl) | 1994-12-24 | 2006-12-29 | Univ Cambridge Tech | Zastosowanie kwasu nukleinowego |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| US6093400A (en) | 1996-08-09 | 2000-07-25 | Cel Sci Corporation | Modified HGP-30 peptides, conjugates, compositions and methods of use |
| CN1233187A (zh) | 1996-08-09 | 1999-10-27 | 病毒技术公司 | HIVp－17肽片段、含有该片段的组合物及其制造和使用方法 |
| US6031647A (en) | 1996-10-23 | 2000-02-29 | Nortel Networks Corporation | Stable power control for optical transmission systems |
| US5972339A (en) | 1997-11-13 | 1999-10-26 | The General Hospital Corporation | Method of eliciting anti-HIV-1 helper T cell responses |
| US20040106136A1 (en) | 1999-01-25 | 2004-06-03 | Musc Foundation For Research Development | Method for testing drug susceptibility of HIV |
| CN1297932A (zh) * | 1999-11-30 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸 |
| BR0016510A (pt) * | 1999-12-23 | 2002-08-27 | Medical Res Council | Aperfeçoamentos em ou relacionados as respostas imunes ao hiv |
| FR2803307A1 (fr) | 1999-12-30 | 2001-07-06 | Centre Nat Rech Scient | Lignees de lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo |
| US20040105871A1 (en) | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
| CN1312275A (zh) * | 2000-03-07 | 2001-09-12 | 上海博德基因开发有限公司 | 一种新的多肽——人热休克蛋白15和编码这种多肽的多核苷酸 |
| AU5929101A (en) | 2000-04-28 | 2001-11-12 | Us Gov Health & Human Serv | Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines |
| DE60026199T2 (de) | 2000-05-18 | 2006-11-23 | Geneart Ag | Synthetische Gene für gagpol und deren Verwendungen |
| AUPQ776100A0 (en) | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
| CA2419822C (en) * | 2000-08-14 | 2011-02-08 | Gary J. Nabel | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| CU23235A1 (es) | 2001-02-28 | 2007-09-26 | Ct Ingenieria Genetica Biotech | POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA |
| IL160809A0 (en) | 2001-09-20 | 2004-08-31 | Glaxo Group Ltd | HIV-gag CODON-OPTIMISED DNA VACCINES |
| AUPR842501A0 (en) | 2001-10-23 | 2001-11-15 | Epipop Pty Ltd | A method for identification and development of therapeutic agents |
| DE60325838D1 (de) | 2002-03-19 | 2009-03-05 | Glaxo Group Ltd | Imidazoquinolinamine als adjuvantien für hiv dna vakzine |
| RU2238946C2 (ru) | 2002-04-22 | 2004-10-27 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Искусственный белок-иммуноген tci, содержащий множественные ctl-эпитопы основных антигенов вич-1, искусственный ген tci, кодирующий полиэпитопный белок-иммуноген tci |
| EP1506223B1 (en) | 2002-05-16 | 2005-11-16 | Bavarian Nordic A/S | Fusion protein of hiv regulatory/accessory proteins |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| PL218318B1 (pl) | 2002-05-16 | 2014-11-28 | Bavarian Nordic As | Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych |
| WO2004002415A2 (en) | 2002-06-27 | 2004-01-08 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
| NZ544011A (en) | 2003-06-10 | 2009-02-28 | Univ Melbourne | Immunomodulating compositions uses therefor and processes for their production |
| CN102010463A (zh) | 2003-09-17 | 2011-04-13 | 杜克大学 | 共有/祖先免疫原 |
| US20070275010A1 (en) | 2003-09-18 | 2007-11-29 | Mark Feinberg | Mva Vaccines |
| JP2007534302A (ja) * | 2003-09-24 | 2007-11-29 | オクソン セラピュティクス リミテッド | Ｈｉｖ医薬 |
| GB0323840D0 (en) | 2003-10-10 | 2003-11-12 | Ist Superiore Sanita | Vaccines |
| EP1687022A4 (en) | 2003-11-12 | 2008-02-13 | Medical Res Council | RENTA: HIV IMMUNOGEN, AND USES OF RENTA |
| US20090169503A1 (en) * | 2004-07-09 | 2009-07-02 | The Government Of The United States, As Represented By The Secretary Of Dept Of H&Hs | Dna-based vaccination of retroviral-infected individuals undergoing treatment |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2006026667A2 (en) | 2004-08-27 | 2006-03-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes |
| US8000900B2 (en) | 2004-09-21 | 2011-08-16 | Microsoft Corporation | Association-based predictions of pathogen characteristics |
| US20060095241A1 (en) | 2004-10-29 | 2006-05-04 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
| US8478535B2 (en) | 2004-10-29 | 2013-07-02 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
| US20060160070A1 (en) | 2004-10-29 | 2006-07-20 | Microsoft Corporation | Association-based epitome design |
| JP5122983B2 (ja) | 2005-02-24 | 2013-01-16 | メディカル リサーチ カウンシル | Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用 |
| BRPI0613025A2 (pt) * | 2005-07-11 | 2010-12-14 | Globeimmune Inc | composiÇço para reduzir a resistÊncia a um agente, mÉtodo para a preparaÇço de um veÍculo de levedura e uso da composiÇço |
| BRPI0504117A (pt) | 2005-09-05 | 2007-05-22 | Fundacao De Amparo A Pesquisa | epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção |
| KR20080106467A (ko) | 2006-03-10 | 2008-12-05 | 펩트셀 리미티드 | Ｈｉｖ 조절 또는 보조 단백질의 펩타이드, 그 조성물 및 이용 방법 |
| GB0608368D0 (en) | 2006-04-28 | 2006-06-07 | Isis Innovation | Process for making Oligopeptides |
| CA2670804A1 (en) | 2006-05-19 | 2007-11-29 | Sanofi Pasteur Inc. | Immunological composition |
| WO2008142479A2 (en) | 2006-08-25 | 2008-11-27 | The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services | Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus |
| US8198082B2 (en) | 2007-03-28 | 2012-06-12 | Hiroshima University | Method of determining chicken embryonic stem cells |
| AU2008246139B2 (en) * | 2007-04-26 | 2013-11-21 | Merck Sharp & Dohme Llc | Synthetic expression vectors for insect cells |
| WO2009009743A2 (en) * | 2007-07-12 | 2009-01-15 | Institute For Advance Study | Sequence optimization for expression of a foreign gene |
| BRPI0821998A2 (pt) | 2008-01-16 | 2019-08-27 | Opal Therapeutics Pty Ltd | composições de imunomodulação e usos para a mesma. |
| JP5984388B2 (ja) * | 2008-07-16 | 2016-09-06 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン |
| EP2161279A1 (en) | 2008-08-29 | 2010-03-10 | Centre National de la Recherche Scientifique | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies |
| US8709775B2 (en) | 2008-08-29 | 2014-04-29 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| WO2010037402A1 (en) * | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| ES2699685T3 (es) | 2008-11-18 | 2019-02-12 | Beth Israel Deaconess Medical Ct Inc | Vacunas antivíricas con inmunogenicidad celular mejorada |
| US20120308593A1 (en) | 2009-09-17 | 2012-12-06 | Sanofi Pasteur, Inc. | Immunological Compositions for HIV |
| EA201270108A1 (ru) | 2009-10-08 | 2012-08-30 | Бавариан Нордик А/С | Формирование полиспецифического t-клеточного ответа против вич у человека |
| EP2488649B1 (en) | 2009-10-16 | 2019-04-03 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
| WO2011082422A2 (en) | 2010-01-04 | 2011-07-07 | The Johns Hopkins University | Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications |
| CN103370333A (zh) | 2010-11-10 | 2013-10-23 | 埃斯特韦实验室有限公司 | 高免疫原性hiv p24序列 |
| EP2620446A1 (en) * | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| WO2020237027A1 (en) | 2019-05-22 | 2020-11-26 | Gilead Sciences, Inc. | Combination of a tlr7 modulating compound and an hiv vaccine |
| CN114828884A (zh) | 2019-05-22 | 2022-07-29 | 埃利克斯疗法公司 | 用于疫苗的剂量方案 |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
-
2012
- 2012-01-27 EP EP12382031.8A patent/EP2620446A1/en not_active Withdrawn
-
2013
- 2013-01-28 BR BR112014018396-1A patent/BR112014018396B1/pt active IP Right Grant
- 2013-01-28 WO PCT/EP2013/051596 patent/WO2013110818A2/en not_active Ceased
- 2013-01-28 EP EP22195110.6A patent/EP4163290A1/en active Pending
- 2013-01-28 JP JP2014553750A patent/JP6306514B2/ja active Active
- 2013-01-28 CA CA2862172A patent/CA2862172C/en active Active
- 2013-01-28 KR KR1020147023946A patent/KR102108149B1/ko active Active
- 2013-01-28 RU RU2014135053A patent/RU2648791C2/ru active
- 2013-01-28 IN IN6164DEN2014 patent/IN2014DN06164A/en unknown
- 2013-01-28 KR KR1020197018840A patent/KR102140778B1/ko active Active
- 2013-01-28 US US14/374,334 patent/US9988425B2/en active Active
- 2013-01-28 RU RU2018104969A patent/RU2721274C2/ru active
- 2013-01-28 MX MX2014009091A patent/MX358711B/es active IP Right Grant
- 2013-01-28 AU AU2013213564A patent/AU2013213564B2/en active Active
- 2013-01-28 NZ NZ734689A patent/NZ734689A/en unknown
- 2013-01-28 CN CN201910705866.5A patent/CN110372798A/zh active Pending
- 2013-01-28 CN CN201380006995.6A patent/CN104080800B/zh active Active
- 2013-01-28 NZ NZ723229A patent/NZ723229A/en unknown
- 2013-01-28 NZ NZ628756A patent/NZ628756A/en unknown
- 2013-01-28 EP EP13701288.6A patent/EP2807185B1/en active Active
- 2013-01-28 ES ES13701288T patent/ES2932407T3/es active Active
-
2014
- 2014-07-16 ZA ZA2014/05204A patent/ZA201405204B/en unknown
- 2014-07-23 IL IL233771A patent/IL233771B/en active IP Right Grant
- 2014-07-25 MX MX2018010483A patent/MX2018010483A/es unknown
-
2017
- 2017-09-28 US US15/718,635 patent/US10815278B2/en active Active
-
2018
- 2018-03-08 JP JP2018041572A patent/JP6749357B2/ja active Active
- 2018-05-03 US US15/970,216 patent/US11325946B2/en active Active
- 2018-05-10 AU AU2018203264A patent/AU2018203264B2/en active Active
-
2019
- 2019-08-11 IL IL268629A patent/IL268629B/en active IP Right Grant
-
2021
- 2021-04-29 US US17/244,042 patent/US11919926B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509707A5 (OSRAM) | ||
| RU2014135053A (ru) | Иммуногены для вакцинации против вич | |
| US12162907B2 (en) | Subunit vaccine for treatment or prevention of a respiratory tract infection | |
| CN104884082B (zh) | 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 | |
| JP2008529558A5 (OSRAM) | ||
| JP2014530010A5 (OSRAM) | ||
| JP2016533332A5 (OSRAM) | ||
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| JP2018512856A5 (OSRAM) | ||
| JP2012501959A5 (OSRAM) | ||
| US9388225B2 (en) | Modified coiled coil type proteins having improved properties | |
| JP2013501038A5 (OSRAM) | ||
| JP2013532971A5 (OSRAM) | ||
| JP2013507907A5 (OSRAM) | ||
| CN114213548B (zh) | 同时诱导抗多种病毒的免疫应答的方法 | |
| JP2016508143A5 (OSRAM) | ||
| TW202130363A (zh) | 變異型ｒｓｖ ｆ蛋白質及其利用 | |
| CN117279659A (zh) | 人偏肺病毒疫苗 | |
| JP2014504297A5 (OSRAM) | ||
| ES2713962T3 (es) | Vacuna para prevenir la enfermedad de edema porcino | |
| JP2012516140A5 (OSRAM) | ||
| JP2016520534A5 (OSRAM) | ||
| CN107344969A (zh) | 一种纳米流感疫苗及构建方法和应用 | |
| JP2006523185A5 (OSRAM) | ||
| JPWO2018074558A1 (ja) | 複合ポリペプチド単量体、細胞浸透機能を有する当該複合ポリペプチドの単量体の会合体、及び、当該会合体を有効成分とする皮下、皮内、経皮又は筋肉内投与用ノロウイルスコンポーネントワクチン |